株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の乳癌治療市場の機会分析

US Breast Cancer Therapy Market Opportunity Analysis

発行 KuicK Research 商品コード 335071
出版日 ページ情報 英文 700 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
米国の乳癌治療市場の機会分析 US Breast Cancer Therapy Market Opportunity Analysis
出版日: 2015年07月09日 ページ情報: 英文 700 Pages
概要

乳癌は、乳房組織に影響を及ぼす悪性腫瘍の一種で、その発生率は世界中で増加しています。また、アメリカ人女性の中でも、罹患率と死亡率が高い、高頻度の癌です。

当レポートでは、米国の乳癌治療市場について調査分析し、発生率と罹患率、市場の概要、臨床パイプライン、主要薬、上市薬、特許分析などについて、体系的な情報を提供しています。

第1章 米国の乳癌の発生率と罹患率

第2章 米国の乳癌治療市場の概要

  • 現在の市場シナリオ
  • 米国の乳癌治療薬のパイプラインの概要

第3章 米国の乳癌治療市場の動向

  • 有利な市場パラメーター
  • 商品化の課題

第4章 米国の乳癌治療市場の将来見通し

第5章 乳癌治療薬の機序

第6章 米国の乳癌治療薬の臨床パイプライン:企業別、相別

  • 研究
  • 前臨床
  • 臨床
  • 第0相
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 認証前
  • 認証済み

第7章 米国の上市済み乳癌治療薬の臨床考察と特許分析:企業別

第8章 米国の臨床パイプラインにおける中止・中断された乳癌治療薬

  • 開発報告なし
  • 中止
  • 市場からの撤退
  • 中断

第9章 競合情勢

  • AbbVie
  • Agilent Technologies
  • ARIAD Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Biodesix
  • BioMarin Pharmaceutical
  • Boehringer Ingelheim
  • Bristol Mayer Squibb
  • Celgene Corporation
  • Dako A/S
  • Debiopharm
  • Dyax
  • エーザイ
  • Eli Lily
  • Exelixis
  • GalaxoSmithKline
  • Incyte Corporation
  • Ligand Pharmaceuticals
  • Merck
  • Navidea Biopharmaceuticals
  • Nektar Therapeutics
  • Novartis
  • Onyx pharmaceuticals
  • Pfizer
  • Roche
  • Sanofi
  • Sun Pharmaceuticals

図表

目次

Breast cancer is a type of malignancy that affects breast tissue and its incidences are increasing across the globe. It is also one of the most common cancers in American women which cause high morbidity and mortality rates. It affects both gender but most of the cases have been found to be related to females as compared to males. Data shows that the numbers of breast cancer incidences and death has remained stagnant with slight change in each year as compared to previous years. It also reflects that much change has not been observed despite use of better breast cancer therapeutics. So, it has become imperative to identify the solutions with which breast cancer could be treated effectively. Pharmaceutical companies are investing significantly in this segment to formulate effective strategy to prevent future breast cancer incidences.

Several breast cancer therapeutics have been introduced for providing higher safety and efficacy levels. These therapies belong to wide range of categories out of which some of them have achieved blockbuster status. Monoclonal antibodies (mAbs) are one of most widely used therapeutics owing to high safety, efficacy and specificity along with minimized side effects. Breast cancer market in US took a major leap when Genentech's monoclonal antibody (mAb) Herceptin got FDA's approval in 1998. Other big pharmaceutical companies soon followed the lead and introduced breast cancer monoclonal antibodies in US. Presently, the high cost of these medicines marketed makes it difficult for breast cancer patients to introduce them in their regular therapeutic regime. It is expected that in the near future, these companies will launch cost effective breast cancer medicines. Many pharmaceutical companies are also exploring the different areas for the development of efficient breast cancer therapeutics.

US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). The inhibition of HER2 is its basic mechanism to prevent the growth and proliferation of breast cancer in women. It was approved in 2012 by the FDA for the treatment of or late-stage metastatic HER2-positive breast cancer patients.

Various pharmaceutical companies are expected to introduce novel breast cancer medicines and technologies in future. Most of them are at different stages of clinical trials and would be introduced in coming years. However, the cost of pharmacologically superior therapeutics is quite high due to which limited breast cancer patients include them in their therapeutic regime. In future, the high cost breast cancer medicines will be replaced by affordable medicines due to advancements in technologies. Nanotechnology based breast cancer medicines are being developed whose introduction in US may take time. New molecular targets are also being investigated that would help in development of innovative medicines in coming years. These developments shows that US breast cancer market will increase as new products would be introduced. In this way, future of breast cancer therapeutics in US seems to be optimistic.

"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:

  • US Breast Cancer Incidence & Prevalence
  • US Breast Cancer Therapy Market Overview
  • US Breast Cancer Drug Clinical Pipeline by Company & Phase
  • US Breast Cancer Drug Clinical Pipeline: 251 Drugs
  • Majority Drugs in Phase-II Trials: 73 Drugs
  • Marketed Breast Cancer Drugs in US: 32 Drugs
  • Breast Cancer Patent Analysis

Table of Contents

1. US Breast Cancer Incidence & Prevalence

2. US Breast Cancer Therapy Market Overview

  • 2.1 Current Market Scenario
  • 2.2 US Breast Cancer Drug Pipeline Overview

3. US Breast Cancer Therapy Market Dynamics

  • 3.1 Favorable Market Parameters
  • 3.2 Commercialization Challenges

4. US Breast Cancer Therapy Market Future Prospects

5. Mechanism of Breast Cancer Drugs

6. US Breast Cancer Drug Clinical Pipeline by Company & Phase

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Clinical
  • 6.4 Phase-0
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-II/III
  • 6.9 Phase-III
  • 6.10 Preregistration
  • 6.11 Registered

7. Marketed Breast Cancer Drug Clinical Insight & Patent Analysis by Company in US

  • 7.1 Albumin-Bound Paclitaxel (Abraxane)
  • 7.2 Anastrozole (Arimidex®)
  • 7.3 Capecitabine (Xeloda®)
  • 7.4 Docetaxel (Taxotere®)
  • 7.5 Eribulin (Halaven®)
  • 7.6 Everolimus (Afinitor®)
  • 7.7 Exemestane (Aromasin®)
  • 7.8 Fluoxymesterone
  • 7.9 Fulvestrant (Faslodex®)
  • 7.10 Gadobutrol
  • 7.11 Gemcitabine (Gemzar®)
  • 7.12 Goserelin (Zoladex®)
  • 7.13 Ixabepilone (Ixempra®)
  • 7.14 Lapatinib (Tykerb®)
  • 7.15 Letrozole (Femara®)
  • 7.16 Paclitaxel (Taxol®)
  • 7.17 Palbociclib (Ibrance™)
  • 7.18 Pertuzumab (Omnitarg™)
  • 7.19 Pertuzumab Companion Diagnostic (HER2 FISH pharmDx)
  • 7.20 Pertuzumab Companion Diagnostic (HercepTest)
  • 7.21 Raloxifene (Evista®)
  • 7.22 Tamoxifen Oral Liquid (Soltamox®)
  • 7.23 Tc 99m Tilmanocept (Lymphoseek®)
  • 7.24 Technetium Tc 99m Sulfur Colloid Diagnostic Injection
  • 7.25 Temsirolimus (Fareston®)
  • 7.26 Trastuzumab (Herceptin®)
  • 7.27 Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
  • 7.28 Trastuzumab Companion Diagnostic (HER2 FISH pharmDx)
  • 7.29 Trastuzumab Companion Diagnostic (HercepTest)
  • 7.30 Trastuzumab Emtansine (Kadcyla®)
  • 7.31 Vinorelbine
  • 7.32 Vitamin B12 Fluorescent-Analogues (CobalaFluor Green™, CobalaFluor Red™)

8. Discontinued & Suspended Breast Cancer Drug in Clinical Pipeline in US

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Preregistration-Submission Withdrawal
  • 8.4 Suspended

9. Competitive Landscape

  • 9.1 AbbVie
  • 9.2 Agilent Technologies
  • 9.3 ARIAD Pharmaceuticals
  • 9.4 AstraZeneca
  • 9.5 Bayer
  • 9.6 Biodesix
  • 9.7 BioMarin Pharmaceutical
  • 9.8 Boehringer Ingelheim
  • 9.9 Bristol Mayer Squibb
  • 9.10 Celgene Corporation
  • 9.11 Dako A/S
  • 9.12 Debiopharm
  • 9.13 Dyax
  • 9.14 Eisai
  • 9.15 Eli Lily
  • 9.16 Exelixis
  • 9.17 GalaxoSmithKline
  • 9.18 Incyte Corporation
  • 9.19 Ligand Pharmaceuticals
  • 9.20 Merck
  • 9.21 Navidea Biopharmaceuticals
  • 9.22 Nektar Therapeutics
  • 9.23 Novartis
  • 9.24 Onyx pharmaceuticals
  • 9.25 Pfizer
  • 9.26 Roche
  • 9.27 Sanofi
  • 9.28 Sun Pharmaceuticals

List of Figures

  • Figure 1-1: US -Estimated Breast Cancer Incidences, 2013-2015
  • Figure 1-2: US - Estimated Breast Cancer Deaths, 2013-2015
  • Figure 1-3: US -Estimated Incidences of Female Breast Cancer, 2013-2015
  • Figure 1-4: US -Estimated Female Breast Cancer Deaths, 2013-2015
  • Figure 1-5: US -Female Breast Cancer Incidence Compare to Others Cancers, 2015
  • Figure 1-6: US -Female Breast Cancer Deaths as compared to other Cancers, 2015
  • Figure 1-7: Diagnosis of Breast Cancer in Different Genders
  • Figure 1-8: US -Estimated Male Breast Cancer New Cases, 2013-2015
  • Figure 1-9: US -Estimate Male Breast Cancer Deaths, 2013-2015
  • Figure 2-1: US - Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
  • Figure 2-2: US -Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
  • Figure 2-3: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
  • Figure 2-4: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
  • Figure 2-5: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
  • Figure 2-6: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
  • Figure 2-7: US - Suspended Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
  • Figure 2-8: US -Suspended Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
  • Figure 3-1: US Breast Cancer Market Drivers
  • Figure 3-2: US Breast Cancer Therapy Market Commercialization Challenges
  • Figure 5-1: Type of Breast Cancer Treatment
  • Figure 5-2: Type of Breast Cancer Surgery
  • Figure 5-3: Mechanism of Trastuzumab
  • Figure 5-4: Mechanism of Docetaxel
  • Figure 5-5: Mechanism of Tamoxifen
  • Figure 9-1: AbbVie-Clinical Pipeline
  • Figure 9-2: ARIAD-Clinical Pipeline
  • Figure 9-3: Celgene Clinical Pipeline
  • Figure 9-4: Debiopharm-Clinical Pipeline
  • Figure 9-5: Eisai-Clinical Pipeline

List of Tables

  • Table 1-1: US -Estimated Number of New Cases for Female Breast Cancer by State, 2015
  • Table 1-2: US -Estimated Number of Deaths for Breast Cancer by State, 2015
Back to Top